Our projects
Our portfolio reflects the Triquetra Medicines development model: identifying therapeutic opportunities with substantial scientific and clinical validation that remain underserved by conventional pharmaceutical business models. By focusing on these opportunities, we can pursue innovative medicines with lower development risk, greater efficiency, and the potential for broad patient access.
TRQ001 - for acute migraine
An innovative treatment approach for acute migraine based on an active substance with established therapeutic and clinical validation. Following regulatory review in Europe, the program has progressed directly to Phase II clinical development.
Demonstrating the strength of our model, this milestone was achieved at a fraction of the cost and with substantially lower residual risk than conventional development programs in this indication.
TRQ002 - bleeding shock
A new treatment modality with pre-clinical and clinical validation
TRQ003 - hypertension and end-organ protection
An enhanced Angiotensin II receptor blocker approach designed to improve cardiovascular and end-organ protection.
TRQ004 - diet-induced dyslipidaemia
A novel, validated therapy approach to treat diet-induced dyslipidaemia and consequences
Triquetra Medicines AB is a private limited company incorporated in Sweden with registered number 559219-9888. Triquetra Medicines™ is an EU-registered trademark.
Copyright © 2026 Triquetra Medicines AB; All Rights Reserved